Search research articles
Contact Us
Filters
Showing results (61-70 of 84) with videos related to
Page
of 9
Sort By:
Epidemiologie, Mikrobiologie, Imunologie : Casopis Spolecnosti Pro Epidemiologii a Mikrobiologii Ceske Lekarske Spolecnosti J.E. Purkyne
|
October 15, 2013
[Dengue fever cases in Czech workers returning from the Maldives]
Milan Trojánek, Dora Tomíčková, Hana Roháčová, et al.
The Lancet. Respiratory Medicine
|
January 18, 2017
Intravenous zanamivir or oral oseltamivir for hospitalised patients with influenza: an international, randomised, double-blind, double-dummy, phase 3 trial
Francisco M Marty, Joan Vidal-Puigserver, Carol Clark, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
May 25, 2012
Safety of peginterferon alfa-2a plus ribavirin in a large multinational cohort of chronic hepatitis C patients
Samuel S Lee, Stuart K Roberts, Hanna Berak, et al.
International Journal of Public Health
|
October 11, 2020
Chronic hepatitis C virus infection in the Czech Republic and Slovakia: an analysis of patient and virus characteristics
Lubomír Skladaný, Marian Oltman, Soňa Fraňková, et al.
Journal of Hepatology
|
May 24, 2003
Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon nonresponders
Eugene R Schiff, Jules L Dienstag, Selim Karayalcin, et al.
Gastroenterology
|
December 26, 2013
Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B
Scott Fung, Peter Kwan, Milotka Fabri, et al.
Gastroenterology
|
December 17, 2009
Farglitazar lacks antifibrotic activity in patients with chronic hepatitis C infection
John McHutchison, Zachary Goodman, Keyur Patel, et al.
Archives of Internal Medicine
|
January 13, 2006
A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B
Seng Gee Lim, Tay Meng Ng, Nelson Kung, et al.
Scientific Reports
|
May 13, 2021
COVID-19's natural course among ambulatory monitored outpatients
Barbora Weinbergerova, Jiri Mayer, Stepan Hrabovsky, et al.
Journal of Hepatology
|
August 23, 2016
Tenofovir disoproxil fumarate (TDF) vs. emtricitabine (FTC)/TDF in lamivudine resistant hepatitis B: A 5-year randomised study
Scott Fung, Peter Kwan, Milotka Fabri, et al.
Page
of 9
Search research articles
Search
Showing results (61-70 of 84) with videos related to
Sort By:
Page
of 9
Epidemiologie, Mikrobiologie, Imunologie : Casopis Spolecnosti Pro Epidemiologii a Mikrobiologii Ceske Lekarske Spolecnosti J.E. Purkyne
|
October 15, 2013
[Dengue fever cases in Czech workers returning from the Maldives]
Milan Trojánek, Dora Tomíčková, Hana Roháčová, et al.
The Lancet. Respiratory Medicine
|
January 18, 2017
Intravenous zanamivir or oral oseltamivir for hospitalised patients with influenza: an international, randomised, double-blind, double-dummy, phase 3 trial
Francisco M Marty, Joan Vidal-Puigserver, Carol Clark, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
May 25, 2012
Safety of peginterferon alfa-2a plus ribavirin in a large multinational cohort of chronic hepatitis C patients
Samuel S Lee, Stuart K Roberts, Hanna Berak, et al.
International Journal of Public Health
|
October 11, 2020
Chronic hepatitis C virus infection in the Czech Republic and Slovakia: an analysis of patient and virus characteristics
Lubomír Skladaný, Marian Oltman, Soňa Fraňková, et al.
Journal of Hepatology
|
May 24, 2003
Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon nonresponders
Eugene R Schiff, Jules L Dienstag, Selim Karayalcin, et al.
Gastroenterology
|
December 26, 2013
Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B
Scott Fung, Peter Kwan, Milotka Fabri, et al.
Gastroenterology
|
December 17, 2009
Farglitazar lacks antifibrotic activity in patients with chronic hepatitis C infection
John McHutchison, Zachary Goodman, Keyur Patel, et al.
Archives of Internal Medicine
|
January 13, 2006
A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B
Seng Gee Lim, Tay Meng Ng, Nelson Kung, et al.
Scientific Reports
|
May 13, 2021
COVID-19's natural course among ambulatory monitored outpatients
Barbora Weinbergerova, Jiri Mayer, Stepan Hrabovsky, et al.
Journal of Hepatology
|
August 23, 2016
Tenofovir disoproxil fumarate (TDF) vs. emtricitabine (FTC)/TDF in lamivudine resistant hepatitis B: A 5-year randomised study
Scott Fung, Peter Kwan, Milotka Fabri, et al.
Page
of 9